Germany's Merck set to expand its Chinese R&D facilities in coming year

China flag against blue sky
Merck KGaA of Darmstadt, Germany is planning to expand its R&D facilities in China next year in an effort to support development within the growing market segment. (Pixabay)

Merck KGaA of Darmstadt, Germany is poised to expand its R&D facilities in China next year in an effort to support development within the growing market segment.

The company expects the country's biopharma market to grow at a fast pace, and it could eventually represent 20% to 25% of the global market, Nikkei Asian Review reported.

The German company currently develops and produces biopharmaceuticals and materials for organic, light-emitting diode displays in China.

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

As part of the expansion, the company will open a new R&D center in the third-quarter next year in Guangzhou, Guangdong Province, where advanced pharmaceutical and life-science research will be conducted.

“China is a major innovation hot spot and one of our most important growth markets," Kai Beckmann, a member of the company's executive board, told the publication.

Additionally, the company said it will debut a new life sciences center in Nantong, Jiangsu Province, where it currently has drug manufacturing operations. It also plans to launch a twice-a-year startup accelerator program.

The company recently announced it is expanding its basic pharmaceutical technologies operation in Shanghai into a core research hub.

Suggested Articles

IQVIA has kick-started a new matchmaking trial service to “accelerate treatment and vaccine development” against COVID-19.

The move sees Evotec establish a 20-person team in Austria and sign up to work on programs for its Japanese partner.

Back in 2016, Pfizer signed up with CRO Icon to help it, alongside other CROs PPD and Parexel, run its vast trial network.